NEWS

Event

2025/07/01

Bio Asia Taiwan 2025 Corporate Presentation Highlights: A New Hope for Alzheimer’s Patients — Innovative Therapy from Elixiron Biotherapeutics
Media

2025/06/12

Immunotherapy Rising Star Elixiron Raises NT$1 Billion, Secures Rakuten Investment, and Targets Q4 Emerging Stock Board Listing
Media

2025/05/18

FISS 2025 Brings Together Leading Experts to Boost Taiwan’s Immunotherapy Research Capacity
Media

2024/11/28

Taiwan's new drug research and development is accelerating! Anlixirong won the "2024 Moderna Taiwan mRNA Foresight Innovation Award", breaking through the bottleneck of cancer treatment, and vitiligo immune drug entered the second phase of clinical trials
Media

2024/11/13

Elixiron Biotherapeutics Wins Emerging Company of the Year at MIT Technology Review China Life Science Competition
Media

2024/10/24

Why Elixiron Biotherapeutics Secured Funding from Bill Gates — Chairman Hung-Kai Chen Reveals the Key: Precision Medicine, Cross-Disciplinary Applications, and Accelerated Innovation
Research

2024/08/30

Elixiron Immunotherapeutics to Initiate Phase 2 Clinical Trial of Innovative Alzheimer's Drug EI-1071 at Taipei Veterans General Hospital
Media

2024/07/29

Elixiron’s Precision Immunotherapy Wins Outstanding Startup Award
Media

2023/09/29

EI-1071, Elixiron's drug candidate targeting microglia-induced inflammation for treating Alzheimer's disease has received the approval for a clinical trial in Taiwan
Research

2023/09/08

EI-001, Elixiron's drug candidate for treating vitiligo, has received approval for a clinical trial in China from the National Medical Products Administration
Scholarly Communication

2023/08/25

Elixiron partners with Yang-Ming University to jointly develop new immunotherapy technology for head and neck cancer - novel drug combining tumor macrophage-targeting antibody with interleukin-10 fusion protein
Scholarly Communication

2023/05/25

A new mechanism of IFN-γ in the pathogenesis of vitiligo reveald by a discovery from the collaborative research of Chang-Gung University and Elixiron

: 1; 2; 3